On June 4, 2025 Purple Biotech Ltd. ("Purple Biotech" or "the Company") (NASDAQ/TASE: PPBT), a clinical-stage company developing first-in-class therapies that seek to overcome tumor immune evasion and drug resistance, reported a poster presentation on its novel CAPTN-3 tri-specific antibody platform, will be featured at the Annual Congress of the European Association for Cancer Research (EACR) 2025, being held in Lisbon, Portugal from June 16 – 19, 2025 (Press release, Purple Biotech, JUN 4, 2025, View Source;id=351926&p=2377908&I=1206939-c7Z3G6f3m8 [SID1234653719]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

EACR poster details are as follows:

Abstract #: EACR25-1964
Title: "CAPTN-3: A novel platform of conditionally activated T cell and NK cell engagers"
Session Title: Immunotherapy
Session Date and Time: June 17, 2025, from 10:45 to 20:00
Presenting Author: Dr. Hadas Reuveni, Vice President of R&D, Purple Biotech

Abstracts related to the EACR meeting will be published online following the presentation. For more information, please visit the EACR 2025 website.

On June 4, 2025 Vividion Therapeutics, Inc. (Vividion), a clinical-stage biopharmaceutical company, and a wholly owned and independently operated subsidiary of Bayer AG, reported it has secured exclusive worldwide rights to develop and commercialize the clinical-stage Werner helicase (WRN) covalent inhibitor VVD-214 (RO7589831), strengthening and complementing its innovative oncology development pipeline (Press release, Vividion Therapeutics, JUN 4, 2025, View Source [SID1234653718]). VVD-214 was discovered and developed under an exclusive worldwide collaboration and license agreement initiated between Vividion and Roche in 2020. Vividon utilizes innovative discovery technologies to unlock difficult-to-drug targets with strong disease-links, and to develop small molecule precision therapeutics for devastating cancers and immune disorders.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Preliminary data from a first-in-human study presented at the recent American Association for Cancer Research (AACR) (Free AACR Whitepaper) Annual Meeting showed that VVD-214 is well tolerated and has promising signs of activity. Vividion will continue the clinical development of VVD-214 within the company’s pipeline of innovative investigational therapeutics for cancers and immune disorders.

WRN is a DNA repair enzyme and a highly sought-after synthetic lethal target for treatment of cancers with microsatellite instability (MSI). By inhibiting WRN, VVD-214 aims to cause lethal DNA damage in cancers with high microsatellite instability while minimizing harm to healthy cells.

"Bringing VVD-214, the only clinical-stage covalent inhibitor of WRN in development worldwide, into our portfolio marks an incredibly exciting moment for Vividion," said Aleksandra Rizo, M.D., Ph.D., Chief Executive Officer of Vividion. "We are eager to progress development of this compound, building on the encouraging clinical data we’ve seen to date, as part of our mission to transform treatment for patients with cancer and other serious diseases."

The Phase I clinical trial (NCT06004245) is evaluating VVD-214 as a monotherapy and in combination with pembrolizumab as a treatment option for patients with solid tumors that display high MSI or deficient mismatch repair (dMMR) including but not limited to colorectal, endometrial, ovarian and gastric cancers. Treatment options for these patients today are limited, and a majority will relapse or become refractory to immune checkpoint inhibitors. The initial data, recently presented at AACR (Free AACR Whitepaper) by Timothy Yap, M.B.B.S., Ph.D., clinical investigator and professor of Investigational Cancer Therapeutics at The University of Texas MD Anderson Cancer Center, showed early signals of efficacy for VVD-214 in a range of solid tumor types with high MSI.1

"VVD-214 is showing promising potential to improve treatment options for patients suffering from MSI-high cancers, a population with high unmet medical need," said Christian Rommel, Ph.D., Global Head of Research and Development at Bayer’s Pharmaceuticals Division. "It underscores the ability of Vividion’s chemoproteomics technology to identify and advance new treatment opportunities for challenging and intractable diseases, and will be a valuable addition to the company’s portfolio."

Vividion also has ongoing Phase I trials evaluating an oral KEAP1 activator in solid tumors, an oral STAT3 inhibitor in solid and hematologic malignancies, and an oral RAS-PI3Kα inhibitor in advanced solid tumors. The company is advancing multiple innovative drug discovery programs toward the clinic and has a growing pipeline of opportunities emerging in early discovery in the fields of oncology and immunology leveraging its chemoproteomics platform.

On June 4, 2025 TOLREMO therapeutics AG (TOLREMO)), a clinical stage biotechnology company pioneering non-oncogene addiction in cancer, reported data from its ongoing Phase I study of TT125-802, a novel, orally administered bromodomain inhibitor of CBP/p300, for patients with advanced solid tumors who have relapsed or are refractory to standard-of-care therapies, including an abstract published at the 2025 American Society of Clinical Oncology (ASCO) (Free ASCO Whitepaper) annual meeting (Press release, TOLREMO, JUN 4, 2025, View Source [SID1234653717]). Updated data from the study was discussed at TOLREMO’s SAB meeting during ASCO (Free ASCO Whitepaper) and recorded in a virtual ASCO (Free ASCO Whitepaper) data update.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

To date TT125-802 shows impressive anti-tumor activity in advanced solid tumors, including deep and durable responses in non-small cell lung cancer (NSCLC). In addition, TT125-802 demonstrates a best-in-class safety profile without thrombocytopenia, the primary toxicity associated with its class of inhibitors.

"Five out of seven NSCLC patients on this study experienced tumor shrinkage following progression on their prior therapy. The two patients with KRAS-G12C- or EGFR-mutant NSCLC – the two tumor types we had preclinically selected as target indications – each showed deep and durable responses to single agent TT125-802. There remains a large and urgent need for more effective and tolerable therapies, and TT125-802 has the potential to offer an improved therapeutic option through resistance-targeted combinations," said Florian Vogl, M.D., PhD, Chief Medical Officer at TOLREMO.

"EGFR- and KRAS-targeted therapies have historically been limited by intrinsic and acquired resistance. Inhibiting transcriptional mechanisms of resistance via CBP/p300 represents an exciting and much needed opportunity for more effective and tolerable therapies. TT125-802 has shown impressive activity in NSCLC even as a monotherapy, and I look forward to combining the drug with EGFR and KRAS-G12C inhibitors to provide better treatment options to my patients," added Pasi Jänne, M.D., PhD, Scientific Advisory Board member at TOLREMO and Senior Vice President for Translational Medicine and the Director of the Belfer Center for Applied Cancer Science at the Dana-Farber Cancer Institute and a Professor of Medicine at Harvard Medical School.

"The best-in-class safety and activity in solid tumors is particularly notable because we didn’t set out to develop a CBP/p300 inhibitor – initially, TT125-802 was developed phenotypically to inhibit non-oncogene addiction in cancer," said Stefanie Flückiger-Mangual, PhD, CEO and co-founder of TOLREMO. "By starting with the biology around transcriptional addiction, it led us to CBP/p300 as a novel target in this space and yielded best-in-class chemistry, enabling a wider therapeutic window and broadening the clinical potential of our asset both in hematological malignancies as well as in solid tumors."

Dr. Jänne and Dr. Omar Saveedra Santa Gadea, a medical oncologist at NEXT Oncology Hospital Quirónsalud in Barcelona, Spain also shared their perspective on the importance of these results, including specific review of clinical case studies as part of an ASCO (Free ASCO Whitepaper) video update at View Source

On June 4, 2025 RAPT Therapeutics, Inc. (Nasdaq: RAPT), a clinical-stage immunology-based biopharmaceutical company focused on discovering, developing and commercializing novel therapies for patients living with inflammatory and immunological diseases, reported that members of the RAPT management team will participate in the following investor conferences in June (Press release, RAPT Therapeutics, JUN 4, 2025, https://investors.rapt.com/news-releases/news-release-details/rapt-therapeutics-participate-upcoming-investor-conferences-1 [SID1234653715]):

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Goldman Sachs 46th Annual Global Healthcare Conference – Fireside chat on Tuesday, June 10, 2025 at 9:20 a.m. ET
UBS Spring Biotech Conference – Investor one-on-one meetings on Tuesday, June 24, 2025
To access the live webcast or subsequent archived recording of the Goldman Sachs fireside chat, please visit the RAPT Therapeutics website at https://investors.rapt.com/events-and-presentations.

On June 4, 2025 Oncovita, a biotechnology company developing innovative virus-based immunotherapies for cancer treatment, reported that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation (ODD) to its lead investigational therapy, MVdeltaC, for the treatment of pleural mesothelioma—a rare and aggressive cancer with high unmet medical need and limited therapeutic options (Press release, Oncovita, JUN 4, 2025, View Source [SID1234653714]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

MVdeltaC is a novel immunotherapy based on a genetically modified attenuated Schwarz strain measles virus, engineered to selectively replicate in tumour cells and stimulate a potent anti-cancer immune response. This approach combines direct tumor cell lysis and immune system activation, with the goal of improving outcomes for patients with advanced solid tumors, including pleural mesothelioma.

"Receiving Orphan Drug Designation from the FDA for MVdeltaC marks a major milestone for Oncovita and validates our approach of harnessing the potential of measles vaccine viruses to treat solid tumors, particularly rare and devastating cancers such as pleural mesothelioma," said Stéphane Altaba, CEO of Oncovita. "This regulatory support strengthens our strategy to advance innovative immunotherapies as we prepare to enter clinical development with MVdeltaC by 2026."

"With this designation, Oncovita is now well-positioned to enter the U.S. market with its modified attenuated measles virus for the treatment of pleural mesothelioma. This recognition highlights the promise of this novel approach against one of the most aggressive cancers in medicine," added Dr. Stéphane Champiat, MD, PhD, Head of Medical Affairs at Oncovita.

The FDA’s Office of Orphan Products Development grants Orphan Drug Designation to support the development of therapies for rare diseases affecting fewer than 200,000 people per year in the United States. This designation provides several benefits for the development of such therapies, including tax credits for eligible clinical trials, waiver of FDA application fees, and up to seven years of market exclusivity following product approval.